Overview
- Bayer reported a net loss of €963 million for the third quarter after booking roughly €1 billion in additional provisions tied to U.S. legal disputes.
- The company raised its full-year expectation for special charges to €3.5–4.0 billion from €2.5–3.5 billion.
- Adjusted EBITDA increased 20.8% to €1.51 billion, beating forecasts as cost reductions in the agribusiness offset pressure in pharmaceuticals.
- Open U.S. glyphosate lawsuits rose to about 65,000, and new provisions reflected settlement agreements, a rise in filings, and a negative ruling in a PCB case.
- Bayer reaffirmed its currency-adjusted 2025 outlook, and CEO Bill Anderson voiced confidence that legal risks can be materially reduced by the end of 2026.